Incyte Co. Forecasted to Post Q2 2025 Earnings of $1.19 Per Share (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY) – Research analysts at William Blair lowered their Q2 2025 earnings per share (EPS) estimates for shares of Incyte in a note issued to investors on Tuesday, April 23rd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will earn $1.19 per share for the quarter, down from their previous forecast of $1.23. William Blair has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $3.85 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.31 EPS and Q4 2025 earnings at $1.35 EPS.

INCY has been the subject of a number of other research reports. Oppenheimer reduced their price objective on Incyte from $92.00 to $84.00 and set an “outperform” rating for the company in a research report on Wednesday. Truist Financial cut their target price on Incyte from $91.00 to $84.00 and set a “buy” rating for the company in a research report on Wednesday, February 14th. JMP Securities downgraded Incyte from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. Jefferies Financial Group initiated coverage on Incyte in a report on Friday, February 23rd. They set a “buy” rating and a $81.00 price target for the company. Finally, Stifel Nicolaus raised their price target on Incyte from $67.00 to $68.00 and gave the company a “hold” rating in a report on Wednesday, February 14th. Nine equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $75.50.

Incyte Price Performance

Shares of INCY stock opened at $51.18 on Wednesday. The stock has a 50 day moving average of $56.90 and a two-hundred day moving average of $57.73. The company has a current ratio of 3.55, a quick ratio of 3.36 and a debt-to-equity ratio of 0.01. Incyte has a 12 month low of $50.27 and a 12 month high of $75.74. The company has a market capitalization of $11.49 billion, a P/E ratio of 19.31, a P/E/G ratio of 1.19 and a beta of 0.65.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.09). Incyte had a net margin of 16.17% and a return on equity of 12.56%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company earned $0.44 EPS. Incyte’s revenue for the quarter was up 9.3% compared to the same quarter last year.

Institutional Investors Weigh In On Incyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC increased its holdings in Incyte by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 531,625 shares of the biopharmaceutical company’s stock valued at $33,381,000 after purchasing an additional 37,932 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in Incyte by 13.6% in the third quarter. State of Alaska Department of Revenue now owns 64,309 shares of the biopharmaceutical company’s stock valued at $3,714,000 after purchasing an additional 7,695 shares during the last quarter. Royal Bank of Canada grew its stake in Incyte by 85.3% in the third quarter. Royal Bank of Canada now owns 987,052 shares of the biopharmaceutical company’s stock valued at $57,021,000 after acquiring an additional 454,416 shares during the period. RFG Advisory LLC acquired a new position in Incyte in the fourth quarter valued at about $206,000. Finally, Raymond James & Associates acquired a new position in Incyte in the fourth quarter valued at about $2,291,000. Institutional investors own 96.97% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.